Literature DB >> 7858682

Problems with the report of the Expert Panel on blood cholesterol levels in children and adolescents.

T B Newman1, A M Garber, N A Holtzman, S B Hulley.   

Abstract

An Expert Panel convened by the National Cholesterol Education Program has recommended selective screening and treatment of children for high blood cholesterol levels, based on family history of cardiovascular disease or high blood cholesterol. This recommendation is problematic for several reasons. First, the recommended diets are likely to cause only a slight decrease in low-density lipoprotein cholesterol levels, the projected benefits of which will be offset by a similar decrease in high-density lipoprotein cholesterol levels. Lack of efficacy of the recommended diets could lead to use of more restrictive diets or to cholesterol lowering drugs. Second, even under optimistic assumptions, beneficial effects of cholesterol intervention will be small and delayed for many decades. As a result, childhood cholesterol-lowering efforts will not be cost-effective. Third, the Expert Panel's recommendations do not address important gender differences. Girls have higher average cholesterol levels than boys. They will therefore qualify for more dietary and drug treatment despite their lower age-adjusted risk of heart disease and the lack of association between cholesterol levels and cardiovascular mortality in women. Finally, recent evidence from randomized trials, cohort studies, and animal experiments suggests that cholesterol lowering may have serious adverse effects. This evidence was not discussed in the Expert Panel's report. Given current evidence, any screening and treatment of children for high blood cholesterol levels is, at best, premature.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7858682     DOI: 10.1001/archpedi.1995.02170150021003

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  6 in total

Review 1.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits.

Authors:  S Tonstad
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

Review 3.  Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.

Authors:  Anthony S Wierzbicki; Adie Viljoen
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

Review 4.  Choices for treatment of hyperlipidaemia.

Authors:  S Tonstad
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

5.  Short-term change in body mass index in overweight adolescents following cholesterol screening.

Authors:  Nipa Doshi; Eliana M Perrin; Suzanne Lazorick; Denise Esserman; Michael J Steiner
Journal:  Arch Pediatr Adolesc Med       Date:  2009-09

6.  Individual-, family-, community-, and policy-level impact of a school-based cardiovascular risk detection screening program for children in underserved, rural areas: the CARDIAC Project.

Authors:  Lesley Cottrell; Collin John; Emily Murphy; Christa L Lilly; Susan K Ritchie; Eloise Elliott; Valerie Minor; William A Neal
Journal:  J Obes       Date:  2013-06-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.